Vincerx Pharma(VINC) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2024 Financial Results Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 — Vincerx Pharma, Inc. (N ...